On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
- 70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
- Surveys by JMA, FTC Provide Evidence for Discussions on Generics
October 16, 2006
- COMMENTARY／Original and Generic Makers Should Cooperate for Stable Supply
September 11, 2006
- COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
- TOPICS 2 articles
August 28, 2006
- COMMENTARY／Government Increases Efforts to Promote Clinical Research
August 28, 2006
- Blockbuster Sales of International Majors in 2005: Rankings of Companies and Therapeutic Areas Keiji Nakamura, Ph.D. Pharma Forum Institute, Kamakura, Japan http://www.pharma-fi.com/index.html
August 21, 2006
- COMMENTARY 3 articles
August 7, 2006
- 5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
- COMMENTARY：New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
- COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
- COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
- Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
- Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
- COMMENTARY 3 articles
June 19, 2006
- Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
- Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
- Incident in PI Trial in UK 5 articles
May 8, 2006
- COMMENTARY 3 articles
April 24, 2006
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…